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HLA-mismatched stem cell transplantation from non-inherited maternal antigen 
(NIMA) complementary donors is known to produce stable engraftment without 
inducing severe GVHD.  We treated two patients with AML and one patient with SAA 
with HLA-mismatched stem cell transplantation (SCT) from NIMA complementary 
donors (NIMA-mismatched SCT).  The presence of donor and recipient-derived blood 
cells in the peripheral blood of recipient (donor microchimerism) and donor was 
documented respectively by amplifying NIMA-derived DNA in 2 of the 3 patients.  
Graft rejection occurred in the SAA patient who was conditioned with a 
fludarabine-based regimen.  Grade III and grade IV acute GVHD developed in patients 
with AML on day 8 and day 11 acute GVHD respectively, and became a direct cause of 
death in one patient.  The findings suggest that intensive conditioning and 
immunosuppression after stem cell transplantation are needed in NIMA-mismatched 
SCT even if donor and recipient microchimerisms is detectable in the donor and 
recipient before SCT.  
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  In allogeneic stem cell transplantation (SCT) from HLA-mismatched donors, severe 
acute GVHD and graft rejections occurs at he higher rate than SCT from HLA-matched 
donors (1, 2).  Recently, allogeneic SCT from non-inherited maternal antigen (NIMA) 
complementary donors has received attentions as one of the methods that potentially 
overcome the barrier of HLA incompatibility.  It is well known that a small number of 
maternal blood cells exist in the newborn’s blood, and in turn, blood cells derived from 
children can be detected in the mother’s blood long after labor.  This phenomenon is 
referred to as fetomaternal microchimerism.  The existence of fetomaternal 
microchimerism suggests that immunological tolerance of hematopoietic cells takes 
place both in mother and child.  Van Rood et al (3) reported the incidence of chronic 
GVHD was significantly lower in mother-to-child SCTs than in father-to-child SCTs.  
Their findings also suggest that HLA-haploidentical NIMA complementary siblings 
can be alternative donor candidates when there is no HLA-matched donor.  Shimazaki 
et al (4) reported five patients treated with allogeneic SCT from two or three loci 
mismatched familiy donors who had a small number of recipient-derived cells in their 
blood before SCT.  Engraftment occurred in all patients, and although acute GVHD 
developed in all five, their severity was grade I or II except for one patient who 
developed grade III acute GVHD.  Ichinohe et al (5) reported that in 
HLA-haploidentical SCTs, NIMA mismatches in the graft-versus-host (GVH) 
direction, was associated with a lower risk of severe acute GVHD compared to IPA 
mismatches.   
  Based on these backgrounds, we treated two AML patients and one SAA patient with 
SCT from NIMA-mismatched sibling donors.  Graft rejection and severe acute GVHD 
occurred despite the fact that donor of recipient-derived michrochimerisms were 
shown in donor and recipient. 
Case report 
Case 1: A 27-year-old man was diagnosed as having chronic myloid leukemia (CML) 
in myeloid crisis.  He underwent an HLA-matched unrelated bone marrow 
transplantation in September 1999.  However, he relapsed with CML in blastic crisis in 
October 2000.  He received allogeneic peripheral blood hematopoietic stem cell 
transplantation from a NIMA complementary dizygotic sibling in November 2002.  A 
fever of 38℃ occurred on day 3 after transplantation and erythema developed in upper 
and lower extremities on day 8.  A diagnosis of acute GVHD, which met the criteria of 
hyperacute GVHD (6, 7) was made through skin biopsy findings.  The patient’s GVHD 
responded to the treatment and both erythema and icterus disappeared on day 26.  The 
complete donor chimerism was confirmed on day 17 by microsatellite marker analysis.  
Imatinib mesylate was administered on day 21 and he was in molecular remission on 
day 58.  However, CML recurred as subcutaneous nodules on day 153 and the patient 
died of CML on day 203. 
Case 2: A 15-year-old woman was diagnosed as having SAA in 2000.  She did not 
respond to all kinds of therapy including ATG and anabolic steroids, and required 
frequent transfusions.  An HLA-matched donor was absent either in relatives or in the 
bone marrow banks.  Allogeneic bone marrow transplantation from the NIMA 
complementary sister was performed in September 2003.  Michrochimerism was 
revealed in both the patient and donor (8).  Her neutrophil count rose to 750 /μl on day 
25, but it became 0/μl following high fever associated with hyperferritinemia (24490 
ng/dl).  Virus-associated hemophagocytic syndrome was suspected and foscarnet was 
administered without any effect.  A chimerism analysis performed on day 34 revealed 
the absence of donor-derived cells in both the peripheral blood and bone marrow, thus 
leading to the diagnosis of secondary graft failure.  She received an infusion of 1.65 x 
106 /kg of peripheral blood CD34+ cells collected from the marrow donor without 
conditioning due to the deteriorating clinical condition, but no hematological recovery 
occurred.  She underwent a cord blood cell transplantation (CBT) following 
conditioning with Flu, 125 mg/m2; melphalan, 160 mg/m2 and TBI at 4 Gy on day 89 
after the first transplantation.  She achieved a complete reconstitution of hematopoiesis 
after CBT and remains well 33 months after CBT.    
Case 3: In January 2002, a 32-year-old man was diagnosed to have acute myeloid 
leukemia (AML) with a normal karyotype.  He achieved a complete remission 
following standard chemotherapy.  A year later, he relapsed with acute lymphocytic 
leukaemia with the Philadelphia chromosome (Ph+ALL).  He was treated with 
chemotherapy consisting of daunorubicin, vincristine, L-asparaginase, and 
prednisolone, followed by the administration of imatinib mesylate, but did not achieve 
a complete remission.  There was no HLA-matched family member.  The 
michrochimerism by NIMAs possessed by the patient was documented in the blood of 
one brother.  He received allogeneic SCT from this NIMA complementary brother.  He 
became febrile from day 2 and erythema appeared diffusely on the generalized skin.  
He was diagnosed to have hyperacute GVHD.  His skin GVHD deteriorated thus 
leading to a diagnosis of grade III acute GVHD.  Bohrus methylprednisolone therapy 
could not improve the symptoms of acute GVHD.  As a result, the patient died of 
thrombotic microangiopathy associated with acute GVHD on day 47. 
 
Results and discussion 
This study is observational.  The incidence of grade II to IV acute GVHD and graft 
failure in patients who were transplanted from HLA haploidentical NIMA 
complemetary siblings has been reported to be 40-50% and 0-18% respectively (3, 5).  
Based on the results of these studies, HLA haploidentical siblings whose NIMA is 
complementary to that of a patient are thought to be a possible donor candidate when 
HLA matched donors are unavailable.  However, our experience of hyperacute GVHD 
and graft rejection in the present report raises a concern about the efficacy of 
HLA-mismatched SCT from NIMA complementary siblings. 
  Tables 1 and 2 summarize the patient characteristics and outcome of SCT for the 
three patients.   Although the HLA disparity was one locus in the GVH direction in case 
1, acute GVHD appeared on day 8 before neutrophil engraftment and rapidly 
progressed to grade III.  Case 3 also developed hyperacute GVHD despite the fact that 
michrochimerism was documented in the donor’s blood.  Acute GVHD is known to 
occur frequently before engraftment of neutrophil in recipient of HLA-mismatched 
SCT (6, 7).  In the analysis of SCTs between NIMA-complementary family members 
described by Ichinohe et al (5), the presence of acute GVHD was observed from day 10.  
The presence of the recipient-specific microchimerism did not necessary predict low 
incidence of acute GVHD in this study, in line with our experience.  Our findings 
suggest the necessity of intensive immunosuppressive therapy to prevent acute GVHD 
such as ATG (9, 10) or alemtuzumab (11) even when a donor shows recipient-specific 
microchimerism.  Since case 1 had received HLA-matched unrelated bone marrow 
transplantation before undergoing the second SCT from a NIMA complementary 
sibling, recipient dendritic cells were probably replaced by the cells of the unrelated 
donor.  The dendritic cells of a recipient play an important role in the development of 
acute GVHD (12, 13).  The absence of the patient-derived dendritic cells, which were 
educated to tolerate donor T cells, may be responsible for hyperacute GVHD of the 
patients.   
Case 2 was conditioned with fludarabine-based regimen which was known to 
ensure engraftment of bone marrow from HLA-matched unrelated donors in AA 
patients (14).  Microchimerism by donor cells was documented in the patient.  
Nevertheless, SCT from the donor ended up with secondary graft rejection.  Although 
the number of of CD34+ cells infused (1.4 x 106 /kg) was relatively low, the minimal 
number of CD34+ cells in the successful SCT was 1.26 x 106 /kg in the report by 
Shimazaki et al  (4) and 1.3 x 106 /kg in the report by Ichinohe et al (5).  It is therefore 
necessary to intensify the conditioning regimen to prevent graft rejection when 
HLA-mismatched SCTs from NIMA complementary siblings are administered to 
patients with AA even if microchimerism by donor cells is documented in the recipient. 
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